EDP Biotech is merging with New Day Diagnostics to speed up the development of disease testing.

There’s a new day coming for diagnostics and it’s all happening because of a merger. EDP Biotech and New Day Diagnostics are combining to help with the expedited development and commercialization of diagnostic tests.

The newly merged company will keep the New Day Diagnostics name.   The merger will bring together EDP Biotech’s expertise as an established and growing specialty diagnostic developer and Contract Research Organization (CRO) with New Day Diagnostics’ robust pipeline of diversified diagnostic tests and commercialization capabilities.

Knoxville, TN-based EDP Biotech develops ColoPle, an aid in diagnosis for detecting colorectal cancers and polyps early, as well as serves a growing roster of diagnostic companies with its full-service CRO focused on In-Vitro Diagnostics (IVD), development, testing, and commercialization, and operates a CLIA lab providing Business-to-Business (B2B) and Direct-to-Consumer (DTC) testing, multiplex assays, research, and validation services.

Boca Raton, FL-based New Day Diagnostics brings a diversified pipeline of physician Point-of-Care (POC) and Physician Mediated-DTC tests to the combined entity. These include a first-to-market DTC celiac disease test and additional offerings targeting infectious diseases, ovarian cancer, and prostate cancer. 

“By joining forces with EDP Biotech, we are strengthening our position as a leading provider of fast, accurate, and affordable diagnostic tests,” said Navroze Mehta, Founder and CEO of New Day Diagnostics. “Together, we will pioneer advancements in diagnostic testing, improving patient lives through early detection and intervention.”

Mehta will serve as Executive Chairman of the combined entity following the merger.